Guardant Health And Academic Collaborators To Present Clinical Utility Of Guardant360 For Solid Tumor Cancers
Thomas Jefferson University, University of California at San Francisco, MD Anderson and University of Pennsylvania to present data on a liquid biopsy platform for genomic sequencing at AACR.
REDWOOD CITY, Calif., April 8, 2015 /PRNewswire/ -- Guardant Health® today announced that six abstracts submitted by leading cancer institutes highlighting the performance and clinical utility of Guardant360 have been accepted for presentation at the 2015 American Association for Cancer Research (AACR) Annual Meeting. The meeting, from April 18-22, 2015 in Philadelphia, is the largest of its kind and brings together researchers and thought leaders dedicated to conquering cancer.
Guardant Health's biopsy-free blood test, Guardant360®, has been on the market since June 2014. Numerous leading oncologists are currently using the product to identify in real-time emerging tumor genomic alterations to unlock potentially overlooked treatment options for their patients. The data to be presented at AACR will highlight the clinical utility of Guardant360 for solid tumor cancers, such as colorectal, breast and pancreatic cancers, as well as detail its clinical performance versus tumor tissue to correctly identify actionable genomic alterations.
With only two vials of blood, Guardant360 digitally sequences billions of genomic data points to identify tumor genomic alterations at greater than 99.9999 percent specificity. These alterations are critical for clinical decisions and are reported in about half the time and with none of the risk of tissue biopsies. The Guardant360 platform gives oncologists and patients a simpler, faster and more accurate perspective of their treatment options, resulting in targeted therapies for genomic alterations.
"Guardant360 is giving oncologists and the biomedical community an unprecedented way to monitor and treat cancer in real-time with a simple blood test," said AmirAli Talasaz, co-founder, president and COO of Guardant Health. "As the market leader in liquid biopsy, Guardant is honored that its academic collaborators will present first-of-its-kind data at the upcoming AACR annual meeting that showcases the performance and clinical utility of blood-based comprehensive genomic profiling of solid tumors via Guardant360."
The schedule of poster presentations from Guardant Health and/or its customers is as follows:
Date and Time: Sunday, April 19 from 1-5 pm ET
Title: Comparison of mutational spectra in metastatic tumors and cell-free DNA in breast cancer patients
Abstract: 618
Location: Section 26
Poster Board Number: 16
Presenters: Kara N. Maxwell, University of Pennsylvania, Philadelphia, PA
Date and Time: Monday, April 20 from 1-5 pm ET
Title: Biopsy-Free Comprehensive tumor profiling of 1,000+ consecutive cancer patients using a CLIA-certified commercial test and its clinical utility
Abstract: 2403
Location: Section 21
Poster Board Number: 6
Presenters: Eric Collisson, UCSF, San Francisco, CA
Date and Time: Wednesday, April 22 from 8 am-Noon ET
Title: Prospective clinical application of circulating cell-free DNA sequencing in metastatic colorectal cancer
Abstract: 5236
Location: Section 22
Poster Board Number: 7
Presenters: Maria Pia Morelli, MD Anderson Cancer Center, Houston, TX
Date and Time: Wednesday, April 22 from 8 am-Noon ET
Title: Clinical Utility of Circulating Tumor DNA (ctDNA) in Advanced and Metastatic Breast Cancer (MBC)
Abstract: 4928
Location: Section 7
Poster Board Number: 24
Presenters: Laura K. Austin, Thomas Jefferson University, Philadelphia, PA
Date and Time: Wednesday, April 22 from 8 am-Noon ET
Title: Concordance of Circulating Tumor DNA (ctDNA) and Next-generation Sequencing (NGS) as Molecular Monitoring Tools in Metastatic Breast Cancer (MBC)
Abstract: 4918
Location: Section 7
Poster Board Number: 14
Presenters: Laura K. Austin, Thomas Jefferson University, Philadelphia, PA
Date and Time: Wednesday, April 22 from 8 am-Noon ET
Title: Next-generation sequence analysis of cell-free DNA in patients with chemotherapy-refractory advanced pancreatic adenocarcinoma (PDAC) treated with selumetinib (AZD6244) and erlotinib.
Abstract: 5244
Location: Section 22
Poster Board Number: 15
Presenters: Andrew H. Ko, UCSF Helen Diller Family Comp. Cancer Center, San Francisco, CA
Guardant Health is also an exhibitor at the 2015 AACR Annual Meeting. Company representatives will be available to provide additional information on Guardant Health and its product, Guardant360, at the company's booth, #1157. To learn more, visit www.guardanthealth.com.
About Guardant Health
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The company has raised $100 million in funding from leading venture capital firms and its first product, Guardant360, came to market in 2014. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.
Media Contact:
Kathy Johnson
Consort Partners for Guardant Health
Email: [email protected]
Phone: 415-823-9566
SOURCE Guardant Health
Share this article